Shionogi & Co., Ltd. (4507) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Shionogi & Co., Ltd. (4507:JPX), powered by AI.

Current Price
¥2,787
P/E Ratio
13.9
Market Cap
2.4T
Sector
Healthcare
What is the Shionogi & Co., Ltd. stock price forecast?

Shionogi & Co., Ltd. is currently trading at ¥2,787. View real-time AI analysis on Alpha Lenz.

What is Shionogi & Co., Ltd. insider trading activity?

View the latest insider trading data for Shionogi & Co., Ltd. on Alpha Lenz.

What is Shionogi & Co., Ltd.'s P/E ratio?

Shionogi & Co., Ltd.'s P/E ratio is 13.9.

Shionogi & Co., Ltd.

JPX · 4507
¥2,787+12(+0.41%)Market closedJPX regular session 09:00–15:00 JST
Ask about Shionogi & Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Shionogi & Co., Ltd. trades at a P/E of 13.9 (undervalued) with solid ROE of 13.1%. Operating margin of 35.7% indicates strong profitability.

Ask for details

Company Overview

Shionogi & Co., Ltd. is a leading pharmaceutical company specializing in the research, development, and distribution of pharmaceutical products. Established in Japan in 1878, Shionogi focuses primarily on three therapeutic areas: infectious diseases, pain/CNS, and oncology. The company is known for its commitment to innovation in drug discovery, aiming to address unmet medical needs through advanced healthcare solutions. Notably, Shionogi has made significant contributions to the development of anti-infective medications, including antibiotics and antiviral treatments, positioning itself as a key player in the fight against global health challenges. In addition to pharmaceuticals, Shionogi expands its reach through ventures in healthcare services and bioinformatics. As a prominent entity in the pharmaceutical industry, Shionogi holds strategic partnerships with various global companies and research institutions, enhancing its impact on the international market. With a dedication to enhancing the quality of life, Shionogi & Co., Ltd. continues to play a crucial role in addressing critical health issues through its innovative solutions and robust product pipeline.

CEODr. Isao Teshirogi Ph.D.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees4,955

Company Statistics

FY 2025

Profile

¥2,370,744,384,867Market Cap
¥438,268,000,000Revenue
0.00Shares Out
4,955Employees

Margins

85.44%Gross
52.64%EBITDA
35.73%Operating
45.81%Pre-Tax
38.68%Net

Valuation

13.91P/E
1.74P/B
5.41EV/Sales
8.75EV/EBITDA
16.54P/FCF

Growth (CAGR)

9.36%Rev 3Yr
5.62%Rev 5Yr
12.39%Op Inc 3Yr
3.69%Op Inc 5Yr
14.33%Net Inc 3Yr
6.77%Net Inc 5Yr

Returns

11.48%ROA
13.12%ROE
14.21%ROIC

Financial Health

¥374,795,000,000Cash & Cash Equivalents
¥-201,942,000,000Net Debt
12.69%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Shionogi & Co., Ltd. (ticker: 4507) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 4,955 employees. Market cap is $2.4T.

The current price is 2,787 with a P/E ratio of 13.91x and P/B of 1.74x.

ROE is 13.12% and operating margin is 35.73%. Annual revenue is $438.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Shionogi & Co., Ltd. (4507) Stock Forecast 2026 ¥2,787 — Price, Financials & Analyst Targets | Alpha Lenz